文献速递MDS 与骨髓增殖性肿瘤白血病

锌依赖的突变钙网蛋白多聚化是MPL结合与MPN发病所必需

Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis.
PubMed 文献 · Blood Adv · 2021-01-01

该研究通过广泛突变筛选发现CALRdel52的凝集素基序和锌结合域对其致癌活性关键,锌结合域为多聚体形成及MPL结合所必需;锌螯合可破坏CALRdel52-MPL复合物并优先清除表达CALRdel52的细胞,在MPN患者原代培养中优先抑制突变红系祖细胞生长。

要点

  • CALRdel52的锌结合域是其多聚化、MPL结合及JAK-STAT激活所必需。
  • 锌螯合可破坏CALRdel52-MPL复合物并优先清除CALRdel52表达细胞。
  • 锌螯合在MPN患者原代培养中优先抑制CALRdel52突变红系祖细胞生长。

核心结论

  • 锌是CALRdel52致癌活性所需的关键辅因子,通过促成CALRdel52多聚化及与MPL相互作用发挥作用。
  • 扰动细胞内锌水平可能成为消除CALRdel52致癌活性治疗MPN的新策略。

研究设计与样本

  • 对CALR球状N域进行广泛突变筛选,并开展多聚化、MPL结合及JAK-STAT信号分析。
  • 在造血细胞中行锌螯合处理,并在MPN患者原代培养中比较CALRdel52突变与未突变红系祖细胞生长。

主要发现

  • 鉴定出CALRdel52致癌活性所需的两个基序:聚糖结合凝集素基序和锌结合域。
  • 锌结合域对CALRdel52多聚体形成必需,而多聚体是MPL结合的共同前提。
  • 不能结合锌的CALRdel52变体无法同源多聚化、形成CALRdel52-MPL异源复合物或刺激JAK-STAT信号。
  • 锌螯合处理破坏造血细胞中CALRdel52-MPL复合物,并相对表达其他MPN致癌基因的细胞优先清除表达CALRdel52的细胞。
  • 在MPN患者原代培养中,锌螯合剂相对未突变红系祖细胞优先损害CALRdel52突变红系祖细胞生长。

临床怎么用

  • 锌螯合或扰动细胞内锌水平可能作为针对CALRdel52突变MPN的治疗思路。
  • CALRdel52的锌结合域及多聚化界面可作为干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Calreticulin (CALR) is mutated in the majority of JAK2/MPL-unmutated myeloproliferative neoplasms (MPNs). Mutant CALR (CALRdel52) exerts its effect by binding to the thrombopoietin receptor MPL to cause constitutive activation of JAK-STAT signaling. In this study, we performed an extensive mutagenesis screen of the CALR globular N-domain and revealed 2 motifs critical for CALRdel52 oncogenic activity: (1) the glycan-binding lectin motif and (2) the zinc-binding domain. Further analysis demonstrated that the zinc-binding domain was essential for formation of CALRdel52 multimers, which was a co-requisite for MPL binding. CALRdel52 variants incapable of binding zinc were unable to homomultimerize, form CALRdel52-MPL heteromeric complexes, or stimulate JAK-STAT signaling. Finally, treatment with zinc chelation disrupted CALRdel52-MPL complexes in hematopoietic cells in conjunction with preferential eradication of cells expressing CALRdel52 relative to cells expressing other MPN oncogenes. In addition, zinc chelators exhibited a therapeutic effect in preferentially impairing growth of CALRdel52-mutant erythroblasts relative to unmutated erythroblasts in primary cultures of MPN patients. Together, our data implicate zinc as an essential cofactor for CALRdel52 oncogenic activity by enabling CALRdel52 multimerization and interaction with MPL, and suggests that perturbation of intracellular zinc levels may represent a new approach to abrogate the oncogenic activity of CALRdel52 in the treatment of MPNs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rivera JF, Baral AJ, Nadat F, et al. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis. Blood Adv. 2021. PMID: 33821991. doi:10.1182/bloodadvances.2020002402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。